Liver transplantation is an alternative treatment of hepatocellular carcinoma beyond the Milan criteria

Fan, Huiying; Chen, Teng-Wei; Hsieh, Chung-Bao; Jan, Hsiang-Chun; His, Sheng-Chuan; Chan, De-Chuan; Chu, Chin-Chen; Yu, Jyh‐Cherng

doi:10.1016/j.amjsurg.2009.07.049

Cited by 19 publications

(19 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…At present, surgical resection/liver transplantation is the only treatment modality to confer survival benefit in HCC patients, and the overall 5-year survival rate for HCC patients is less than 5% [3]. The most important reason leading to poor prognosis is intra hepatic metastasis [4].…”

Section: Introductionmentioning

confidence: 99%

MicroRNA-182 downregulates metastasis suppressor 1 and contributes to metastasis of hepatocellular carcinoma

et al. 2012

View full text Add to dashboard Cite

BackgroundmiR-182 is one of the most significantly up-regulated miRNAs in hepatocellular carcinoma (HCC). Metastasis suppressor 1 (MTSS1), one target gene of miR-182, plays an important role in the metastasis of cancers. However, it remains unclear what role does function and mechanism of miR-182 and MTSS1play in HCC.MethodsmiR-182 expression was tested in 86 cases of paired HCC and normal tissues by real-time PCR and the relationships between miR-182 expression and clinicopathological parameters were analyzed. The expression of MTSS1 was evaluated by immunohistochemistry and western blot in the above tissues and its correlation with miR-182 expression was analyzed. Moreover, western blot and invasion assays were performed after transfection of pre-miR-182 or anti-miR-182 to HCC cell lines. In addition, luciferase assays was performed to confirm the regulation of miR-182 on MTSS1.ResultsCompared with normal tissue, miR-182 was up-regulated and MTSS1 was down-regulated in HCC tissues. Moreover, the over-expression of miR-182 was correlated with intrahepatic metastasis (p = 0.034) and poor prognosis (p = 0.039) of HCC patients. There was a negative correlation between miR-182 and MTSS1 expression in both HCC tissues (r = −0.673, p < 0.01) and HCC cell lines (r = −0.931, p = 0.021). Furthermore, the up-regulation of miR-182 resulted in the down-regulation of MTSS1 and increased invasive potential of HUH-1, and reverse results were also confirmed when the expression of miR-182 was inhibited. In addition, the results of the luciferase assay demonstrated the targeted regulation of miR-182 on MTSS1.ConclusionsmiR-182 could promote metastasis of HCC and inhibit the expression of MTSS1. miR-182 and MTSS1 are potential prognostic markers and/or therapeutic targets in HCC.

show abstract

Section: Introductionmentioning

confidence: 99%

MicroRNA-182 downregulates metastasis suppressor 1 and contributes to metastasis of hepatocellular carcinoma

et al. 2012

View full text Add to dashboard Cite

show abstract

“…EASL/AASLD guidelines suggest that resection for HCCs larger than 5 cm should be exceptional because of the high rate of vascular invasion and the dismal prognosis [21]. Fan et al reported that patients with HCC beyond Milan criteria who underwent LT had a better RFS than patients who underwent LR, but there was no diff erence in overall survival [55]. Patients who underwent LR for HCC > 10 cm had a 3-year survival rate of only 32% [56].…”

Section: Pre-transplant Down-stagingmentioning

confidence: 96%

Hepatocellular carcinoma – new trends

Popescu

2010

memo

View full text Add to dashboard Cite

memo Hepatocellular carcinoma -new trends 3/2010 short review 113 © Springer-VerlagPurpose: Hepatocellular carcinoma is one of the most common malignant tumours in the world and the fourth most common cause of mortality, with ongoing changes in what epidemiology, diagnosis and treatment are concerned. Th is paper summarizes current strategies and new trends in HCC diagnosis and treatment.Material and methods: A review of literature integrating personal experience.Results: Th is review emphasizes the epidemiological trends, diagnostic developments and new treatment strategies for HCC, with its particularities for various world regions. Early diagnosis continues to be the key for eff ective therapy.Conclusion: In the era of personalized molecular therapies, the development of molecular classifi cation of HCC using gene signature is urgently needed, allowing the tailoring of HCC medical therapy. Novel molecular targeted therapy should be evaluated in randomized clinical trials as adjuvant therapy to surgery, ablation or TACE.

show abstract

“…Hepatic resection or liver transplantation is restricted to a small minority of patients with HCC (8,9). Greatly-advanced HCC with involvement of the heart is rare (14,15).…”

Section: Discussionmentioning

confidence: 99%

“…Surgeries, including complete surgical resection and liver transplantation, offer the best prognosis for HCC (6,7). However, 70-85% of patients with HCC are not surgical candidates due to advanced liver disease or extrahepatic metastases (8,9). Metastatic right atrial (RA) tumor thrombus is rare in advanced HCC patients, but the prognosis is poor (10,11).…”

Section: Introductionmentioning

confidence: 99%

Long-term survival after chemoembolization of metastatic right atrial tumor thrombus as a presenting feature of hepatocellular carcinoma: A case study

et al. 2012

View full text Add to dashboard Cite

Abstract. Advanced hepatocellular carcinoma (HCC) with invasion into the heart through the hepatic vein is a recognized rare occurrence with an extremely poor prognosis. Patients who present with right heart tumor thrombus have generally been considered inoperable. Although aggressive resection and liver transplantation treatment have previously been performed, the results remain unsatisfactory. However, HCC with extension into the heart usually indicates a contraindication for transcatheter arterial chemoembolization (TACE). In this study, a rare case of HCC with metastatic inferior vena cava (IVC) and right atrial (RA) tumor thrombus was reported. The young patient was admitted to our department due to Budd-Chiari syndrome. Following diagnosis according to CT image findings and laboratory data, the patient underwent TACE therapy. This treatment resulted in a marked reduction in the liver tumor and the right atrial tumor thrombus. Following TACE therapy, the patient survived for 3 years and 10 months and remains alive without any signs of recurrence. This case indicates that TACE therapy can be used successfully for the treatment of advanced HCC with heart tumor thrombus and may result in long-term survival.

show abstract

Liver transplantation is an alternative treatment of hepatocellular carcinoma beyond the Milan criteria

Cited by 19 publications

References 18 publications

MicroRNA-182 downregulates metastasis suppressor 1 and contributes to metastasis of hepatocellular carcinoma

MicroRNA-182 downregulates metastasis suppressor 1 and contributes to metastasis of hepatocellular carcinoma

Hepatocellular carcinoma – new trends

Long-term survival after chemoembolization of metastatic right atrial tumor thrombus as a presenting feature of hepatocellular carcinoma: A case study

Contact Info

Product

Resources

About